middle.news
Noxopharm Engages Novotech to Advance SOF-SKN US FDA Strategy
8:36am on Wednesday 6th of May, 2026 AEST
•
Biotechnology
Read Story
Noxopharm Engages Novotech to Advance SOF-SKN US FDA Strategy
8:36am on Wednesday 6th of May, 2026 AEST
Key Points
Pre-IND meeting preparation with US FDA underway
Novotech engaged to support regulatory strategy
SOF-SKN targets cutaneous lupus and other autoimmune diseases
Sofra platform shows broad therapeutic potential
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE